Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Episode 37 with Dr. Jeanne Loring on human pluripotent stem cells in a mouse model of MS
Episode 45 with Dr. Simon Hametner on the role of iron in MS
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
Recruiting women smokers: the engineering of consent.
Episode 54 with Dr. Jonathan Kipnis: Part 2 on meningeal lymphatic vessels in neuroinflammation, and clinical implications
Episode 53: Part 1 with Dr. Jonathan Kipnis on the discovery of lymphatic vessels in the meninges
American Society for Neurochemistry 46th Annual Meeting
Episode 41 with Dr. Diego Cadavid on a clinical trial of anti-LINGO-1
Episode 58 with Dr. Gavin Giovannoni on the new MS Brain Health initiative
Episode 59 with Dr. Helmut Butzkueven on the new MS Brain Health initiative
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells.
International Society for Neurovascular Disease (ISNVD)
Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system.
Temporal trends in the incidence of multiple sclerosis: a systematic review.
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
FOCiS 2015 Meeting: Immunology by the Bay
Improving the translational hit of experimental treatments in multiple sclerosis.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Gender as risk factor for autoimmune diseases.
Use of fumaric acid esters in psoriasis.
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
12th International Society of Neuroimmunology Congress

Pages